{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:34:33Z","timestamp":1793468073787,"version":"4.5.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS) entails low quality of life for patients and massive societal costs. There is an urgent need for elucidation of disease mechanisms and for rational treatment. Our working hypothesis is that ME\/CFS in a subgroup of patients is associated with functional autoantibodies emerging after an infection, and that plasma-cell depletion with transient reductions in serum immunoglobulins will have a beneficial effect on patients\u2019 symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex<jats:sup>\u00ae<\/jats:sup>) in moderate to severe ME\/CFS, and to assess the clinical course through 12\u201324\u202fmonths follow-up after daratumumab intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a prospective, open-label pilot trial (EudraCT 2022\u2013000281-18). Ten female patients were enrolled. Following 12\u202fweeks run-in, six patients received four daratumumab injections. The next four patients received four, followed by three additional injections from week 14.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All planned treatments were administered, and there were no serious adverse events. Four patients had no significant clinical changes. Six patients experienced marked improvement. For all 10 patients, mean SF-36 Physical Function (SF-36 PF) increased from 25.9 to 55.0 at 8\u20139 months (<jats:italic>p<\/jats:italic>\u202f=\u202f0.002). DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (<jats:italic>p<\/jats:italic>\u202f=\u202f0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. Five of these six patients had major and sustained improvement with a mean SF-36 PF of 88 (range 80\u201395) toward end of follow-up. Mean steps per 24\u202fh was 3,359 (range 1,493\u20136,277) at baseline. At 8\u20139 months, the mean number of steps was 5,862, and 7,392 in the six responders. All five patients with sustained improvement reached a mean step count above 10,000\/24\u202fh for some weeks, and above 15,000 on individual days. Relative reduction of serum IgG levels was 54% in six patients with clinical improvement, and 40% among four with no benefit. Low baseline NK-cell count in blood was significantly associated with lack of clinical response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Subcutaneous daratumumab in 10 ME\/CFS patients was well tolerated. In six patients, treatment was associated with clinical improvement and concurrent transient reduction of serum IgG levels, indicating important pathomechanistic roles for long-lived plasma cells and functional autoantibodies. No definite conclusions should be drawn before a randomized study has been performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>https:\/\/euclinicaltrials.eu<\/jats:uri>, Identifier: 2022-000281-18.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1607353","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:47:01Z","timestamp":1752126421000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis\/chronic fatigue syndrome\u2014a clinical pilot study"],"prefix":"10.3389","volume":"12","author":[{"given":"\u00d8ystein","family":"Fluge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid Gurvin","family":"Rekeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"S\u00f8rland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kine","family":"Alme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Risa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ove","family":"Bruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Johan","family":"Tronstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Mella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-11-402","article-title":"The functional status and well being of people with myalgic encephalomyelitis\/chronic fatigue syndrome and their carers","volume":"11","author":"Nacul","year":"2011","journal-title":"BMC Public Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e0132421","DOI":"10.1371\/journal.pone.0132421","article-title":"The health-related quality of life for patients with Myalgic encephalomyelitis \/ chronic fatigue syndrome (ME\/CFS)","volume":"10","author":"Falk Hvidberg","year":"2015","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/medicina60081215","article-title":"Myalgic encephalomyelitis\/chronic fatigue syndrome: Impact on quality of life (QoL) of persons with ME\/CFS","volume":"60","author":"Muirhead","year":"2024","journal-title":"Medicina"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15620\/cdc:134504","article-title":"Myalgic encephalomyelitis\/chronic fatigue syndrome in adults: United States, 2021-2022","volume":"488","author":"Vahratian","year":"2023","journal-title":"NCHS Data Brief"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1741-7015-9-91","article-title":"Prevalence of myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) in three regions of England: a repeated cross-sectional study in primary care","volume":"9","author":"Nacul","year":"2011","journal-title":"BMC Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fped.2018.00412","article-title":"Estimating prevalence, demographics, and costs of ME\/CFS using large scale medical claims data and machine learning","volume":"6","author":"Valdez","year":"2018","journal-title":"Front Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1471-2377-11-62","article-title":"Evidence for a heritable predisposition to chronic fatigue syndrome","volume":"11","author":"Albright","year":"2011","journal-title":"BMC Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/neurolint15010001","article-title":"ME\/CFS and post-exertional malaise among patients with long COVID","volume":"15","author":"Jason","year":"2022","journal-title":"Neurol Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1038\/s41467-022-32507-6","article-title":"A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity","volume":"13","author":"Kedor","year":"2022","journal-title":"Nat Commun"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0309810","DOI":"10.1371\/journal.pone.0309810","article-title":"Impact of COVID-19 on myalgic encephalomyelitis\/chronic fatigue syndrome-like illness prevalence: a cross-sectional survey","volume":"19","author":"Wood","year":"2024","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1177\/13591053231169191","article-title":"Do diagnostic criteria for ME matter to patient experience with services and interventions? Key results from an online RDS survey targeting fatigue patients in Norway","volume":"28","author":"Kielland","year":"2023","journal-title":"J Health Psychol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1172\/JCI150377","article-title":"Pathomechanisms and possible interventions in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS)","volume":"13","author":"Fluge","year":"2021","journal-title":"J Clin Invest"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.it.2018.04.003","article-title":"Divergent roles of Antiself antibodies during infection","volume":"39","author":"Rivera-Correa","year":"2018","journal-title":"Trends Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","article-title":"Diverse functional autoantibodies in patients with COVID-19","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.tips.2020.11.013","article-title":"Autoantibodies as endogenous modulators of GPCR signaling","volume":"42","author":"Skiba","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1542\/peds.2008-1879","article-title":"Chronic fatigue syndrome after infectious mononucleosis in adolescents","volume":"124","author":"Katz","year":"2009","journal-title":"Pediatrics"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3390\/ijms26062799","article-title":"An in-depth exploration of the autoantibody immune profile in ME\/CFS using novel antigen profiling techniques","volume":"26","author":"Germain","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijcard.2011.10.030","article-title":"Large and small artery endothelial dysfunction in chronic fatigue syndrome","volume":"154","author":"Newton","year":"2012","journal-title":"Int J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/ehf2.12633","article-title":"Peripheral endothelial dysfunction in myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"7","author":"Scherbakov","year":"2020","journal-title":"ESC Heart Fail"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e0280942","DOI":"10.1371\/journal.pone.0280942","article-title":"Endothelial dysfunction in ME\/CFS patients","volume":"18","author":"Sandvik","year":"2023","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"642710","DOI":"10.3389\/fmed.2021.642710","article-title":"Reduced endothelial function in Myalgic encephalomyelitis\/chronic fatigue syndrome-results from open-label cyclophosphamide intervention study","volume":"8","author":"Sorland","year":"2021","journal-title":"Front Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.chest.2021.01.082","article-title":"Insights from invasive cardiopulmonary exercise testing of patients with Myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"160","author":"Joseph","year":"2021","journal-title":"Chest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.chest.2021.08.010","article-title":"Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing","volume":"161","author":"Singh","year":"2022","journal-title":"Chest"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/s0002-9343(97)00087-9","article-title":"Does the chronic fatigue syndrome involve the autonomic nervous system?","volume":"102","author":"Freeman","year":"1997","journal-title":"Am J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/jcm9082531","article-title":"Autonomic phenotypes in chronic fatigue syndrome (CFS) are associated with illness severity: a cluster analysis","volume":"9","author":"S\u0142omko","year":"2020","journal-title":"J Clin Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e149217","DOI":"10.1172\/jci.insight.149217","article-title":"A map of metabolic phenotypes in patients with myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"6","author":"Hoel","year":"2021","journal-title":"JCI Insight"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e89376","DOI":"10.1172\/jci.insight.89376","article-title":"Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy\/chronic fatigue syndrome","volume":"1","author":"Fluge","year":"2016","journal-title":"JCI Insight"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1039\/c6mb00600k","article-title":"Metabolic profiling of a myalgic encephalomyelitis\/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism","volume":"13","author":"Germain","year":"2017","journal-title":"Mol BioSyst"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e0193672","DOI":"10.1371\/journal.pone.0193672","article-title":"Immunoadsorption to remove beta2 adrenergic receptor antibodies in chronic fatigue syndrome CFS\/ME","volume":"13","author":"Scheibenbogen","year":"2018","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.3390\/jcm9082443","article-title":"Myalgic encephalomyelitis\/chronic fatigue syndrome: efficacy of repeat Immunoadsorption","volume":"9","author":"T\u00f6lle","year":"2020","journal-title":"J Clin Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1016\/j.ymthe.2025.01.007","article-title":"Effect of Immunoadsorption on clinical presentation and immune alterations in COVID-19-induced and\/or aggravated ME\/CFS","volume":"33","author":"Anft","year":"2025","journal-title":"Mol Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"101161","DOI":"10.1016\/j.lanepe.2024.101161","article-title":"Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis\/chronic fatigue syndrome and elevated \u03b22-adrenergic receptor autoantibodies: a prospective cohort study","volume":"49","author":"Stein","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fmed.2020.00162","article-title":"Intravenous cyclophosphamide in Myalgic encephalomyelitis\/chronic fatigue syndrome. An open-label phase II study","volume":"7","author":"Rekeland","year":"2020","journal-title":"Front Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-2377-9-28","article-title":"Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series","volume":"9","author":"Fluge","year":"2009","journal-title":"BMC Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e26358","DOI":"10.1371\/journal.pone.0026358","article-title":"Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study","volume":"6","author":"Fluge","year":"2011","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e0129898","DOI":"10.1371\/journal.pone.0129898","article-title":"B-lymphocyte depletion in Myalgic encephalopathy\/ chronic fatigue syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment","volume":"10","author":"Fluge","year":"2015","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.7326\/M18-1451","article-title":"B-lymphocyte depletion in patients with Myalgic encephalomyelitis\/chronic fatigue syndrome: a randomized, double-blind, placebo-controlled trial","volume":"170","author":"Fluge","year":"2019","journal-title":"Ann Intern Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e0307484","DOI":"10.1371\/journal.pone.0307484","article-title":"Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"19","author":"Rekeland","year":"2024","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1194754","DOI":"10.3389\/fmed.2023.1194754","article-title":"Fighting post-COVID and ME\/CFS - development of curative therapies","volume":"10","author":"Scheibenbogen","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1300\/J092v11n01_02","article-title":"Myalgic encephalomyelitis\/ chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols","volume":"11","author":"Carruthers","year":"2003","journal-title":"J Chronic Fatigue Syndr"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/s0895-4356(98)00098-5","article-title":"Translation and performance of the Norwegian SF-36 health survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity","volume":"51","author":"Loge","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1037\/rep0000285","article-title":"The development of a short form of the DePaul symptom questionnaire","volume":"64","author":"Sunnquist","year":"2019","journal-title":"Rehabil Psychol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/s0895-4356(98)00081-x","article-title":"Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project","volume":"51","author":"Ware","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s11136-017-1684-4","article-title":"Norwegian reference values for the short-form health survey 36: development over time","volume":"27","author":"Jacobsen","year":"2018","journal-title":"Qual Life Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","article-title":"The unique properties of IgG4 and its roles in health and disease","volume":"23","author":"Rispens","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.4049\/jimmunol.139.10.3306","article-title":"Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome","volume":"139","author":"Caligiuri","year":"1987","journal-title":"J Immunol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1440643","DOI":"10.3389\/fimmu.2024.1440643","article-title":"Meta-analysis of natural killer cell cytotoxicity in myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"15","author":"Baraniuk","year":"2024","journal-title":"Front Immunol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/art.24556","article-title":"Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus","volume":"60","author":"Park","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/cells9010077","article-title":"Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases?","volume":"9","author":"Benfaremo","year":"2019","journal-title":"Cells"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.56875\/2589-0646.1108","article-title":"Role of anti-CD38 monoclonal antibodies in the treatment of adult immune hematological diseases","volume":"17","author":"Yang","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/bjh.17655","article-title":"Daratumumab in rituximab-refractory autoimmune haemolytic anaemia","volume":"194","author":"Rieger","year":"2021","journal-title":"Br J Haematol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"667515","DOI":"10.3389\/fimmu.2021.667515","article-title":"Case report: resetting the humoral immune response by targeting plasma cells with Daratumumab in anti-phospholipid syndrome","volume":"12","author":"Pleguezuelo","year":"2021","journal-title":"Front Immunol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"649441","DOI":"10.3389\/fimmu.2021.649441","article-title":"The immunomodulatory effect and clinical efficacy of Daratumumab in a patient with cold agglutinin disease","volume":"12","author":"Zaninoni","year":"2021","journal-title":"Front Immunol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/j.bcmd.2023.102724","article-title":"Daratumumab as a novel treatment option in refractory ITP","volume":"99","author":"Vernava","year":"2023","journal-title":"Blood Cells Mol Dis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/jamainternmed.2023.0152","article-title":"Daratumumab for a patient with refractory Antineutrophil Cytoplasmatic antibody-associated Vasculitis","volume":"183","author":"Rixecker","year":"2023","journal-title":"JAMA Intern Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with Daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e003604","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2025.2492774","article-title":"Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"25","author":"Wohlrab","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"2024.06.18.24309100","DOI":"10.1101\/2024.06.18.24309100","article-title":"A causal link between autoantibodies and neurological symptoms in long COVID","volume":"19","author":"Santos Guedes de Sa","year":"2024","journal-title":"medRxiv"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multi-faceted Ecto-enzyme CD38: roles in immunomodulation, Cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front Immunol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e2149675","DOI":"10.1002\/eji.202149675","article-title":"Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches","volume":"53","author":"Merino-Vico","year":"2023","journal-title":"Eur J Immunol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fimmu.2020.00578","article-title":"Autoimmunity-related risk variants in PTPN22 and CTLA4 are associated with ME\/CFS with infectious onset","volume":"11","author":"Steiner","year":"2020","journal-title":"Front Immunol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bbi.2021.03.023","article-title":"Skewing of the B cell receptor repertoire in myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"95","author":"Sato","year":"2021","journal-title":"Brain Behav Immun"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1002\/cncr.27612","article-title":"Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults","volume":"118","author":"Chang","year":"2012","journal-title":"Cancer"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"e0236148","DOI":"10.1371\/journal.pone.0236148","article-title":"Plasma proteomic profiling suggests an association between antigen driven clonal B cell expansion and ME\/CFS","volume":"15","author":"Milivojevic","year":"2020","journal-title":"PLoS One"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-017-1201-0","article-title":"Whole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival","volume":"15","author":"Nguyen","year":"2017","journal-title":"J Transl Med"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbi.2015.09.013","article-title":"Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome","volume":"52","author":"Loebel","year":"2016","journal-title":"Brain Behav Immun"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41590-023-01445-w","article-title":"Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course","volume":"24","author":"Muri","year":"2023","journal-title":"Nat Immunol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bbi.2023.01.006","article-title":"Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome","volume":"109","author":"Franke","year":"2023","journal-title":"Brain Behav Immun"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"7209","DOI":"10.3390\/ijms23137209","article-title":"Long COVID: Association of Functional Autoantibodies against G-protein-coupled receptors with an impaired retinal microcirculation","volume":"23","author":"Szewczykowski","year":"2022","journal-title":"Int J Mol Sci"}],"updated-by":[{"DOI":"10.3389\/fmed.2025.1677216","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1607353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T16:27:42Z","timestamp":1755534462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1607353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":74,"alternative-id":["10.3389\/fmed.2025.1607353"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1607353","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fmed.2025.1677216","asserted-by":"object"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"article-number":"1607353"}}